AMO Pharma, a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, has welcomed Joseph Horrigan as Chief Medical Officer; Alison McMorn as Vice President of Clinical Operations; and Bernard Kiernan as Head of Pharmaceutical Sciences and Manufacturing.
Dr Horrigan comes to AMO Pharma with more than two decades of experience in the pharmaceutical industry and as a paediatric neuropsychiatrist.
Prior to joining AMO Pharma, he held multiple leadership positions in pharmaceuticals and medical research. Most recently he led clinical development programmes in neurodevelopmental disorders at Neuren Pharmaceuticals. He also co-founded and led the company-wide Medicines for Children Advisory Network at GlaxoSmithKline and was Assistant Vice President and Head of Medical Research at Autism Speaks.
McMorn has an extensive background in managing global clinical development programmes and most recently was Director of Clinical Programmes at Shire Pharmaceuticals.
Kiernan has more than 20 years of experience in pharmaceuticals and joins the team from Shire Pharmaceuticals where he was Director for Product Development in global pharmaceutical sciences.
